EZH2 and squamous cell carcinoma: Two of the five carcinomas negative for CD117 were positive for EZH2 using the ≥80% threshold (both squamous cell carcinomas), such that performing both EZH2 and CD117 IHC increased sensitivity from 86% (for CD117 alone) to 92%.